Vanguard Portfolio Management’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
Vanguard Portfolio Management's CORT Position: Q3 2026 in Review
Vanguard Portfolio Management reduced its Corcept Therapeutics (CORT) stake by 5.3% in Q3 2026, selling an estimated $28.8M and leaving 4,777,065 shares worth $550M. The position accounts for 0.02% of the portfolio, ranked #634.
Vanguard Portfolio Management first reported a position in CORT in Q1 2026 and has held it in 3 quarters since. 419 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- Vanguard Portfolio Management held 4,777,065 shares of Corcept Therapeutics worth $550M as of Q3 2026.
- Vanguard Portfolio Management sold 267,573 Corcept Therapeutics shares in Q3 2026, an estimated $28.8M.
- Corcept Therapeutics made up 0.02% of Vanguard Portfolio Management's portfolio in Q3 2026, its #634 holding.
- Vanguard Portfolio Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 419 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.